March 30, 2011 09:26 ET

Equity Research on Mylan Inc. and Watson Pharmaceuticals Inc. -- Generic Drug Makers Benefit From Expiring Rights and Expanding Medicaid Coverage

NEW YORK, NY--(Marketwire - March 30, 2011) - has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Drugs - Generic industry and are offering free analytical research on Mylan Inc. (NASDAQ: MYL) and Watson Pharmaceuticals Inc. (NYSE: WPI). Register with us today at to have free access to this research and speak to one of our pros.

Generic drug makers may be better positioned for growth than their name brand counterparts with the amount of companies facing expiring exclusivity rights. An expanding, budget minded Medicaid program could also help generate revenues for generic drug makers. Visit to see how companies in this industry have grown over the past years and how they are expected to perform in the future. is the Ultimate Trading Environment for investors. If you are considering owning Mylan Inc. and Watson Pharmaceuticals Inc. then you should sign up for a free membership and our complimentary reports today at Over the last 5 years our returns outpaced any of the major indexes. Sign up today to find out what you are missing. 

Mylan Pharmaceuticals is among generic drug makers benefitting from expiring exclusivity deals. The company expects to launch 500 products globally this year, some of which carry limited competition clauses and a few with 180 days of exclusivity. Mylan Inc. report is accessible for free by registering today at

Rising Medicaid costs in 2010 may compel some states to adjust rules to encourage more generic prescriptions. Considering that another 16 million people could be added to the Medicaid program by 2019, emphasizing generic drugs may be necessary to keep the cost of the program down.

The only clear negative factors working against companies within the industry at the moment are legal battles. Watson Pharmaceuticals Inc. is currently being sued by Purdue Pharmaceuticals for allegedly violating a number patents. Watson Pharmaceuticals Inc. report is accessible for free by registering today at

The two Drugs - Generic stocks research reports are available for free by signing up now on


Shine's Room Online is the brain child of David Shine, a 15 year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our disclaimer, visit this link

Contact Information